European Vaccine Initiative

European Vaccine Initiative

November 15, 2013 12:55 ET

European Vaccine Initiative: New Global Strategy for Prevention of Death and Disease From Malaria

Update of the Malaria Vaccine Technology Roadmap Aims for Effective Malaria Vaccines by 2030

HEIDELBERG, GERMANY and WASHINGTON, USA--(Marketwired - Nov. 15, 2013) - The World Health Organization (WHO), together with the European Vaccine Initiative (EVI) as members of the Malaria Vaccine Funders Group, have today launched the updated Malaria Vaccine Technology Roadmap1. In response to recent changes in malaria epidemiology and control, and acknowledging important developments in malaria research since the launch of the original Roadmap in 2006, the strategic goals and priority areas have been expanded and updated by the organisations involved in the development of this joint vision.

Despite major progress during the past decade in terms of reduction in overall mortality -on a global level malaria remains the most devastating disease in children-, one African child died every minute. The past decade has seen major innovations in diagnostic testing, vector control measures, and treatment. Malaria vaccines are the keystone of an integrated public health strategy for defeating malaria.

Priority areas of the Roadmap that have been updated include the standardisation of assays and of clinical trial design and assessment, the objective of ensuring that results from all funded malaria vaccine trials are publicly available within twelve months of the last subject visit, and the commitment to establish a systematic approach in prioritising vaccine candidates, including malaria caused by Plasmodium vivax and Plasmodium falciparum. The Roadmap highlights the degree of collaboration achieved by the global malaria vaccine community in its joint quest to control and ultimately eradicate this devastating disease. EVI is highly committed to the Malaria Vaccine Technology Roadmap and will continue to implement the strategy of the Roadmap in its support for the development of malaria vaccine candidates.

1 Published online 14 November 2013, www.thelancet.com

About EVI:

EVI (European Malaria Vaccine Initiative, EMVI, until 2009) is a leading European non-profit Product Development Partnership with the principal objective of developing effective, accessible, and affordable vaccines against malaria and other diseases of poverty. Since its inception in 1998 EVI has contributed to the development of 32 malaria vaccine candidate formulations with 15 vaccine candidates advancing into phase I clinical trials, three of which have been transitioned for further clinical development in sub-Saharan Africa. EVI leads global efforts in the development of vaccines against diseases of poverty, while also acting as coordinator of several initiatives and consortia to create harmonisation between all global stakeholders in vaccine research. EVI is hosted by Heidelberg University in Germany.

About Malaria Vaccine Funders Group:

Informal group of some of the key funders of malaria vaccine development including the Bill & Melinda Gates Foundation (BMGF), the European & Developing Countries Clinical Trial Partnership (EDCTP), the European Vaccine Initiative (EVI), the European Union, the PATH Malaria Vaccine Initiative (MVI), the US Agency for International Development (USAID), the US National Institute of Allergy and Infectious Disease (NIAID), the Wellcome Trust, and the World Health Organization (WHO).

Contact Information

  • European Vaccine Initiative
    Stefan Jungbluth
    +49-6221-564259
    stefan.jungbluth(at)euvaccine.eu
    www.euvaccine.eu